A one year multicenter, randomized, double-blind, placebocontrolled, parallel group study to evaluate the efficacy and safety of a single intravenous 5 mg dose zoledronic acid for the treatment of osteoporosis in men The primary objectives are to demonstrate the superiority of treatment with zoledronic acid Calcium and Vitamin D relative to placebo Calcium and Vitamin D regarding the percent change of BMD at ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multicenter, Double-Blind,Randomized, Active Controlled Study to Compare the Effect of Long Term Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily in Drug Na?ve Patients with Type 2 Diabetes

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 t.i.d. vs. immediate release carbidopa/levodopa t.i.d. in Parkinsons disease patients requiring levodopa

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Not available Not available

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Etude ouverte, multicentrique, de 24 semaines, évaluant l'efficience clinique de la forme Exelon patch 10 cm2 chez des patients avec une maladie d'Alzheimer (MMSE 10-26) Confirmer l'efficience clinique d'Exelon patch en déterminant en pratique courante le pourcentage de patients qui peuvent atteindre et maintenir pendant au moins 8 semaines la posologie maximale (Exel...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY TO COMPARE THE EFFECT OF 52 WEEKS TREATMENT WITH LAF237 50 MG BID TO METFORMIN UP TO 1000 MG BID IN DRUG NAIVE PATIENTS WITH TYPE 2 DIABETES

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study of quality of life in chronic Spontaneous Urticaria patients and treated by omalizumab (Xolair®) Etude de qualité de vie chez les patients souffrant d'urticaire chronique spontanée et traités par omalizumab (Xolair®) Evaluate the proportion of patients achieving disease control (urticaria control test [UCT] score of greater than or equal to 12) at Week 12 in adult patients with CSU with inadequate response to H1 a...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa- 2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney To assess the treatment effect on progression-free survival (PFS) of patients who receive RAD001 plus bevacizumab versus patients who receive IFN plus bevacizumab based on an estimation of the chance ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Extension to a multicentre, randomized, crossover, open labeldose finding study to compare the safety, efficacy and PK/PD relationship of multiple doses of SOM230 (200, 400 and 600 mcg b.i.d.) and doses of open label of Sandostatin (100 mcg t.i.d.)in acromegalic patients

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multicentre, randomized, double-blind, placebocontrolled, parallel-group phase II study on the efficacy and safety of DEB025 combined with peg-IFN alfa-2a and ribavirin in chronic hepatitis C genotype 1 patients who are previous peg-IFN alfa-2 plus ribavirin treatment-nonresponders To evaluate whether the proportion of patients who achieve cEVR (by Limit of Quantitation, LOQ, i.e. HCV RNA < 25 IU/mL) after 12 weeks of triple therapy with DEB025 600 mg/day combined with peg-IFN...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune